Polpharma Celebrates Being First With Natalizumab In Europe
Proposed Biosimilar Rival To Tysabri Begins EMA Review; Sandoz Has Marketing Rights
Polpharma Biologics has claimed the first biosimilar natalizumab filing in Europe, after the European Medicines Agency accepted the firm’s marketing authorization application for review.
